A Loughborough University student has developed a new medical device that could transform how prostate health is assessed and monitored. Subscribe to our newsletter for the latest sci-tech news ...

Transrectal ultrasound guided (TRUS) biopsy has been the gold standard for prostate cancer diagnosis, but carries a significant risk of urinary tract infection, sometimes requiring hospital admission ...

Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...

Clinical studies of Dr Allen’s US Patented Thermobalancing Therapy in men with benign prostatic hyperplasia or benign prostatic enlargement (BPE or BPH) have demonstrated the efficacy and safety of ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...

Industry trade associations made the case for revisions to draft guidance on clinical testing recommendations for prostate tissue ablation devices in comments earlier this month. The Medical Imaging & ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

The MarketWatch News Department was not involved in the creation of this content. Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and ...

Prostatitis and BPH (benign prostatic hyperplasia) are distinct conditions affecting the prostate gland. Although both conditions involve the prostate, they have different causes, symptoms, treatments ...